The New Breast Recurrence Score Report
It's never been as clear
The newly designed Breast Recurrence Score test report for your ER+, HER2-, early-stage breast cancer patients provides 3 points of clarity to aid in treatment decisions
When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.
How much do ineffective cancer treatments cost the healthcare system? In the US alone, Oncotype IQ tests have saved more than $3.5 billion.
The Eighth Edition AJCC Staging Manual is now effect, and it has changed staging for T1-2 N0 M0 breast cancer patients.
Latest TAILORx Data
The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.
Sign up for Our Healthcare Professional Updates